Clinical Trial Update: Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of KB004 in myelodysplastic syndrome and myelofibrosis, sponsored by Humanigen, Inc., is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelofibrosis

Drugs mentioned

• KB004

Snippet

Sponsor: Humanigen, Inc. | Conditions: Myelodysplastic Syndrome (MDS), Myelofibrosis (MF) | Phase 1, Phase 2 | Status: SUSPENDED